AU2020221839B2 - Bicyclic sulfonamides - Google Patents

Bicyclic sulfonamides Download PDF

Info

Publication number
AU2020221839B2
AU2020221839B2 AU2020221839A AU2020221839A AU2020221839B2 AU 2020221839 B2 AU2020221839 B2 AU 2020221839B2 AU 2020221839 A AU2020221839 A AU 2020221839A AU 2020221839 A AU2020221839 A AU 2020221839A AU 2020221839 B2 AU2020221839 B2 AU 2020221839B2
Authority
AU
Australia
Prior art keywords
substituted
unsubstituted
compound
alkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2020221839A
Other languages
English (en)
Other versions
AU2020221839A1 (en
Inventor
Leonid Beigelman
David Bernard Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aligos Therapeutics Inc
Original Assignee
Aligos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aligos Therapeutics Inc filed Critical Aligos Therapeutics Inc
Publication of AU2020221839A1 publication Critical patent/AU2020221839A1/en
Application granted granted Critical
Publication of AU2020221839B2 publication Critical patent/AU2020221839B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020221839A 2019-02-14 2020-02-12 Bicyclic sulfonamides Ceased AU2020221839B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962805725P 2019-02-14 2019-02-14
US62/805,725 2019-02-14
PCT/US2020/017974 WO2020167984A1 (en) 2019-02-14 2020-02-12 Bicyclic sulfonamides

Publications (2)

Publication Number Publication Date
AU2020221839A1 AU2020221839A1 (en) 2021-08-19
AU2020221839B2 true AU2020221839B2 (en) 2024-09-12

Family

ID=72045615

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020221839A Ceased AU2020221839B2 (en) 2019-02-14 2020-02-12 Bicyclic sulfonamides

Country Status (13)

Country Link
US (1) US11033556B2 (https=)
EP (1) EP3924357A4 (https=)
JP (1) JP2022519764A (https=)
KR (1) KR20210126636A (https=)
CN (1) CN113423712A (https=)
AU (1) AU2020221839B2 (https=)
BR (1) BR112021015864A2 (https=)
CA (1) CA3128061A1 (https=)
IL (1) IL284940A (https=)
MX (1) MX2021009717A (https=)
SG (1) SG11202108835SA (https=)
TW (1) TW202045516A (https=)
WO (1) WO2020167984A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202112741XA (en) 2019-05-31 2021-12-30 Aligos Therapeutics Inc Modified gapmer oligonucleotides and methods of use
CN115160344A (zh) * 2021-04-06 2022-10-11 上海长森药业有限公司 通过口服给药抑制CD4+Treg细胞的药物和方法
EP4399217A2 (en) 2021-09-08 2024-07-17 Aligos Therapeutics, Inc. Modified short interfering nucleic acid (sina) molecules and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10875876B2 (en) * 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CN108264520B (zh) 2017-01-03 2021-12-07 上海长森药业有限公司 用于治疗乙型肝炎的化合物及其用途
CN109251212A (zh) * 2017-07-14 2019-01-22 上海长森药业有限公司 内环硫醚酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途

Also Published As

Publication number Publication date
CN113423712A (zh) 2021-09-21
BR112021015864A2 (pt) 2021-10-05
EP3924357A1 (en) 2021-12-22
EP3924357A4 (en) 2023-02-22
TW202045516A (zh) 2020-12-16
US20200345749A1 (en) 2020-11-05
JP2022519764A (ja) 2022-03-24
SG11202108835SA (en) 2021-09-29
CA3128061A1 (en) 2020-08-20
MX2021009717A (es) 2021-09-14
WO2020167984A1 (en) 2020-08-20
IL284940A (en) 2021-09-30
KR20210126636A (ko) 2021-10-20
AU2020221839A1 (en) 2021-08-19
US11033556B2 (en) 2021-06-15

Similar Documents

Publication Publication Date Title
AU2020253444B2 (en) Pyrrole compounds
JP2017538722A (ja) 置換ヌクレオシド、ヌクレオチド、及びそのアナログ
US11952374B2 (en) Bicyclic compounds
AU2020221839B2 (en) Bicyclic sulfonamides
WO2020214728A1 (en) Bicyclic and tricyclic compounds
EP4594319A1 (en) Bicyclic compounds
US20230382909A1 (en) Bicyclic compounds
US12384779B2 (en) Bicyclic compounds
EP3980406A1 (en) Heterocyclic compounds
WO2021030278A1 (en) Bicyclic compounds

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired